Three endocrinology clinics in Madrid scanned 388 adults with obesity four times over six months on GLP-1 drugs and report that skeletal muscle mass fell by 1.46 kg while mean body weight fell 11.3%. Visceral fat area dropped by 40.6 square centimetres. On those numbers the muscle loss is modest next to the fat loss, which is the reassuring reading and the one likely to travel. It is worth knowing before you accept it that this was a retrospective chart review with no comparison group, and that the body composition was estimated by bioelectrical impedance rather than measured by DXA or MRI.
What the clinics measured
The study is a retrospective real-world observational analysis of 388 adults with obesity treated with GLP-1 receptor agonists and followed for six months in specialist endocrinology practice, alongside lifestyle intervention. Multifrequency bioelectrical impedance analysis was performed at baseline, six weeks, three months and six months. The team used linear mixed models with a random intercept for each patient, plus a fully adjusted model to test the independent contribution of adherence and of obesity phenotype. Participants were 40.7% women, mean age 50.3 years.
Mean weight loss reached 11.3% at six months (p<0.001), which the authors describe as predominantly driven by fat. They report a fat mass reduction of 8.95%, the 40.6 square centimetre fall in visceral fat area, and a decrease in skeletal muscle mass of 1.46 kg. For someone starting at 100 kg, 11.3% is about 11.3 kg off, of which roughly one eighth was skeletal muscle as bioimpedance estimates it. Patients who took the drug as prescribed lost more fat than those who did not. The authors also record improvements in anxiety and binge eating behaviours and a low incidence of adverse events, and report that patients grouped by obesity phenotype showed distinct patterns of fat and muscle loss.
Why the method is the main caveat, not a footnote
Bioelectrical impedance infers body composition from how an electrical current passes through the body, which makes it sensitive to hydration. Rapid weight loss shifts body water, and a shift in body water moves the estimate whether or not tissue has changed. That is not a reason to dismiss the result; it is a reason to treat 1.46 kg as an estimate with a wider margin than a DXA or MRI figure would carry, particularly in people losing weight quickly.
There was also no control group, and every patient received lifestyle intervention alongside the drug, so nothing here separates what the medication did from what the diet and activity advice did. The abstract reports the fat mass change as 8.95% without saying whether that is a relative reduction in fat mass or a change in the share of body weight that is fat, and we could not resolve it from the abstract, so it should not be read as a kilogram figure. The drugs and doses are not named.
Set against what is already on record, the direction is familiar. A 60-study review earlier this month found lean mass falling on these drugs while bone was left alone, and a separate cohort found grip strength holding up over a year of treatment. This study adds real-world scans from routine clinics to that picture; it does not settle it, and it contains no functional measure such as grip strength or gait speed to say whether the muscle that was lost mattered. For the wider question of what these drugs do to the body beyond the scales, see our GLP-1 research hub.
What is not yet known
This is retrospective, single-country, and drawn from specialist clinics whose patients are not a cross-section of everyone taking these drugs. Six months is a short window for a question about muscle, which is a long-run concern. The reported improvements in anxiety and binge eating come without named instruments in the abstract, so we cannot say how they were assessed. The paper is online ahead of print. We read the published abstract in full and not the complete paper.
